Robert Sikes, Ph.D., Associate Professor of Biological Sciences, is the Director of the CTCR. Robert is an expert in prostate cancer who is recognized for his outstanding work in creating cell lines and animal models used throughout the world for studies of prostate cancer metastasis. Robert serves a liason of the CTCR to Thomas Jefferson University/Kimmel Cancer Center, and also is co-director of a DOD training grant for minority undergraduates to perform prostate cancer research. These students also attend enrichment programs discussing health disparities of cancer.
Nicholas
Petrelli, M.D., is the Bank of America Endowed Medical Director
of the HFGCC and responsible for oversight of the clinical and
community
based efforts of the CTCR. One of his initial projects at the HFGCC
was establishing disease site multidisciplinary centers where patients
could see a surgeon, medical and radiation oncologist in one visit
with all the necessary support services such as psychology, social
services, genetic counseling, nurse navigators, nutritionists,
clinical trial nurses and pastoral care.
Rob
Long, B.S., Research Associate III at the University
of Delaware, serves as CTCR Research Core Manager. Rob manages,
maintains and operates
the instruments for users of the Core. He also provides training
for users who wish to work independently.
Chu Zhang, Ph.D., Research Associate III at the University of Delaware,
serves as CTCR Research Coordinator. Her position allows her to facilitate
the interdisciplinary work of the CTCR researchers from all members
of the Cancer Research Alliance. She works with students, fellows,
residents, clinicians and faculty to conduct state-of-the-art research
projects utilizing cell culture, molecular, genetic and physiological
approaches. She can be visited in the CTCR Core Research Lab in room
006 Wolf Hall which she oversees.
Carlton R. Cooper, Ph.D., Assistant Professor of Biological Sciences, is the Community Outreach Coordinator of the CTCR. Carlton is interested in health care disparities that disproportionately affect historically underserved members of the community including patients with HIV. Dr. Cooper also is interested in increasing diversity of patients enrolled in clinical trials, and in increasing the numbers of minority students seeking careers in cancer research.
